WO2016114761A1 - Method for individualized drug therapy - Google Patents

Method for individualized drug therapy Download PDF

Info

Publication number
WO2016114761A1
WO2016114761A1 PCT/US2015/011148 US2015011148W WO2016114761A1 WO 2016114761 A1 WO2016114761 A1 WO 2016114761A1 US 2015011148 W US2015011148 W US 2015011148W WO 2016114761 A1 WO2016114761 A1 WO 2016114761A1
Authority
WO
WIPO (PCT)
Prior art keywords
nsaid
disorders
patient
formulation
cox
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/011148
Other languages
French (fr)
Inventor
Vuong Trieu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autotelic LLC
Original Assignee
Autotelic LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autotelic LLC filed Critical Autotelic LLC
Priority to KR1020157034125A priority Critical patent/KR20160098029A/en
Priority to EP15878203.7A priority patent/EP3245602A4/en
Priority to AU2015377253A priority patent/AU2015377253A1/en
Priority to JP2017536310A priority patent/JP2018508476A/en
Priority to CN201580077772.8A priority patent/CN107408147A/en
Priority to CA2973569A priority patent/CA2973569A1/en
Priority to PCT/US2015/011148 priority patent/WO2016114761A1/en
Priority to PCT/US2015/034738 priority patent/WO2015191473A1/en
Priority to EP15806490.7A priority patent/EP3151822A4/en
Priority to AU2015274895A priority patent/AU2015274895A1/en
Priority to PCT/US2015/034706 priority patent/WO2015191460A1/en
Priority to CN201580040734.5A priority patent/CN106572984A/en
Priority to JP2016571720A priority patent/JP2017517529A/en
Priority to EP15807276.9A priority patent/EP3151823A4/en
Priority to CN201580042156.9A priority patent/CN106572985A/en
Priority to KR1020167015176A priority patent/KR20160091349A/en
Priority to AU2015274908A priority patent/AU2015274908A1/en
Priority to CA2956899A priority patent/CA2956899A1/en
Priority to KR1020167015173A priority patent/KR20160091348A/en
Priority to JP2017516649A priority patent/JP2017517575A/en
Priority to CA2956897A priority patent/CA2956897A1/en
Priority to US14/798,753 priority patent/US20160008371A1/en
Priority to US14/798,737 priority patent/US20160022639A1/en
Priority to TW104142786A priority patent/TW201625307A/en
Priority to PCT/US2016/012914 priority patent/WO2016115057A1/en
Priority to US14/993,037 priority patent/US20160120885A1/en
Priority to TW105109708A priority patent/TW201642906A/en
Priority to TW105109706A priority patent/TW201642854A/en
Publication of WO2016114761A1 publication Critical patent/WO2016114761A1/en
Priority to US15/298,222 priority patent/US20170035787A1/en
Priority to US15/360,971 priority patent/US20170071956A1/en
Priority to US15/490,883 priority patent/US20170326109A1/en
Anticipated expiration legal-status Critical
Priority to US16/173,924 priority patent/US20190125727A1/en
Priority to US16/183,638 priority patent/US20190070201A1/en
Priority to US16/206,953 priority patent/US20190091243A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/50—Molecular design, e.g. of drugs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C99/00—Subject matter not provided for in other groups of this subclass
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • ADRs adverse drug reactions
  • a drug's efficacy against disases is a fundamental issue.
  • side effects or "adverse drug reactions” (“ADRs") caused by a drug can profoundly impact the patient, thus requiring alterations in the treatment plan.
  • ADRs account for -7% of all hospitalizations and consistently rank as one of the most common causes of inpatient death in western countries.
  • ADRs non-steroidal ant i -i nfl ammatory drugs
  • Cyclooxygenase-2 inhibitors is there an association with coronary or renal events?, Current Atherosclerosis Reports 2003;5:1 14-7.)
  • FIG. 1 is a scatterplot graph from McAdams et al. displaying the relationship between LPS-stimulated plasma PGE2 ex vivo, an index of COX-2 activity, and log plasma concentrations of celecoxib at 2, 4, 6, and 24 hours after dosing. PGE2 is expressed as a percentage of predosing values. A variable dose-response is evident. (P , 0.01 vs. placebo).
  • ⁇ Scale ranged from 1 (very good) to 5 (very poor).
  • Patient improvement was defined as a reduction of at least 2 grades from baseline for grades 3 through 5 or a change in grade from 2 tl .
  • Patient worsening was defined as an increase of at least 2 grades from baseline for grades ⁇ through 3, or a change in grade from 4 to 5.
  • t P ⁇ .05 vs placebo;
  • ⁇ [] Scale ranged from 0 to 24 with negative change indicating improvement;
  • # P ⁇ .05 vs naproxen
  • the Celebrex® dosage prescribed for the treatment of osteoarthritis is standardized (e.g., 50, 100, 200 or 400 mg dosage forms) regardless of the gender and age of the patient receiving celecoxib.
  • studies have shown that, on average, elderly patients receiving 100 mg celecoxib doses over a six week period reported almost identical reductions in pain as compared to patients receiving 200 mg celecoxib doses over a six week period.
  • the subjects receiving the 100 nig dose of celecoxib also reported fewer side effects for the duration of the study.
  • the results indicate that patients may experience the same celecoxib efficacy at lower, safer doses. Accordingly, there is a need for improved methods of using NSAIDs in the therapy of arthritic pain.
  • the present invention addresses the the wide variability in the responses individuals have to the same dosage of a drug by setting forth methods for individualizing drug therapy.
  • the methods of the present invention individualize dosages a patient takes, thus maximizing the efficacy of one or more drugs at the lowest doses possible and at the point of care.
  • the present invention can increase drug compliance, reduce costs, and most importantly improve the quality and safety of patient lives.
  • the invention provides methods for individualized therapy of arthritic pain using a non-steroidal anti-inflammatory drug (NSAID).
  • NSAID non-steroidal anti-inflammatory drug
  • the high patient to patient variability in response to a dose of any NSAID makes the mere clinical monitoring of patients an inadequate way to treat patients with this class of drugs. Even the measurement of "blood levels'” (i.e., the ocasional measurement of the drug's concentration in the blood) is unlikely to lead to effective nontoxic regimens.
  • blood levels' i.e., the ocasional measurement of the drug's concentration in the blood
  • a more compressive set of metrics must employed in each patient.
  • the methods claimed herein take advantage of a pharmacokinetic ("PK") analysis for each patient. As such, the claimed methods go beyond the measurement of a single blood level at a single time point.
  • PK pharmacokinetic
  • the claimed methods make use of data from several time points and take advantage of the full scope of PK parameters.
  • the claimed method seeks to determined the individual PK directly.
  • the inventive methods disclosed herein comprise: administering to a first patient suffering from arthritic pain a first NSAID formulation; determining the NSAID 's concentration in the first patient's blood at a plurality of time points after the first NSAID formulation was administered to the first patient; transforming the first patient's NSAID concentration/time data points in to one or more PK parameters; comparing the first patient's values for said PK parameters to a predetermined ranges of values for each PK parameter and if one or more of the first patient's PK parameters fall outside o a predetermined range, designing a new NSAID formulation, wherein the dose of said NSAID can be different from that of the first NSAID formulation.
  • the types and amounts of excipients can also differ from those of the first NSAID formulation, or both.
  • the new NSAID formulation is then administered to the first patient and the steps used to determine the PK parameters are repeated until all the PK parameters used are within said predetermined ranges, and if pain control is adequate and toxicity is tolerable, maintaining the first patient on the NSAID formulation at frequency of administration that satisfied the comparison within predetermined ranges.
  • FIG. 1 is a scatterplot graph displaying the relationship between LPS-stimulated plasma PGE2 ex vivo, an index of COX-2 activity, and log plasma concentrations of celecoxib 2, 4, 6, and 24 hours after dosing.
  • PGE2 is expressed as a percentage of predosing values. A steep but variable dose-response is evident. (P , 0.01 vs. placebo) (from McAdam et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. PNAS. 1999; 96:272-7.)
  • FIG. 3 displays the result of a meta-analysis of the one dose AUC from patients in different age groups.
  • individualized therapy refers to a specific treatment regimen for a patient comprising the administration of one or more drugs, which is the result of analyzing pharmacokinetic and/or pharmacodynamic parameters of the subject to maximize drug efficacy at about the lowest dosage of the drug(s) possible.
  • arthritic pain refers to any pain arising anatomically from the joints and their adjacent bones and non-osseous tissues. Any arthritic pain can be treated by the invention including, without limitation, any pain resulting from an auto-immune, infectious, inflammatory, proliferative, regenerative or degenerative process so involving the joints of an animal or human patient. As such, suitable pain treatable with the current invention includes pain from rheumatoid or osteo arthritis.
  • formulation refers to a combination of active ingredients and excipients wherein each is present in a dosage form at fixed ratios to one another (i.e., fixed percentages of each ingrediant in the dosage form.)
  • first NSAID formulation is the NSAID formulation that is administered to the patient to begin the process by which PK parameters are determined and "new NSAID formulation” is the formulation designed based on the PK parameters produced by the first NSAID formulation.
  • new NSAID formulation is the formulation designed based on the PK parameters produced by the first NSAID formulation.
  • the new NSAID formulation may be a second formulation.
  • second formulation and “second formulation under a second drug regimen” refer to the dosage of one or more drugs an individual receives after performing certain steps of the claimed invention (e.g., after comparing an patient's pharmacokinetic parameters to a predetermined range of values).
  • the second formulation under a second regimen can be, e.g., the same dosage of a drug administered in the first regimen, a lower dose, or a higher dose.
  • first formulation under a first regimen and “first formulation” refer to the dosage of one or more drugs an individual initially receives prior to performing one or more steps of the claimed invention.
  • the first formulation under a first regimen can be, e.g., the standard 100 mg or 200 mg dosages of celecoxib prescribed to patients over 60 kg twice daily for osteoarthritis.
  • NSAID concentration/time data points refers to the amount of NSAID in a unit of volume (e.g., 1 ml of blood from a subject) at a given point in time before or after administration of the NSAID.
  • the phrase "predetermined range of values” refers to a known range of values (e.g., pharmacokinetic parameters) associated with desirable drug efficacy at lower risk doses of a drug (e.g., the C max range corresponding to patients experiencing high drug efficacy at a low dose).
  • the predetermined range of values may be derived from a statistical analysis of a population receiving variable and/or identical doses of one or more drugs.
  • the predetermined range of values can readily be compared to a patient's values (e.g., pharmacokinetic values), associated with one or more drugs.
  • the predetermined ranges are determined (i.e. derived) from other patients for whom there was improved pain levels without significant side effects.
  • Signal side effects refer to side effects that the patient finds intolerable, impair physiologic functions, and/or put the patient at risk for immobility and/or death or combinations thereof.
  • designing refers to changes in the active agent's dose, formulation and/or regiment based on the patient data, using logic and the experience of one of ordinary skill in the art.
  • determining the level of efficacy refers to the use of objective (e.g., pharmacokinetic) and subjective tests (e.g., pharmacodynamic), signs and symptoms to characterize, quantify or evaluate how well symptoms (e.g., pain) are controlled by the administration of the active ingredient (e.g., celecoxib).
  • objective e.g., pharmacokinetic
  • subjective tests e.g., pharmacodynamic
  • signs and symptoms e.g., pharmacodynamic
  • determining the level of toxicity refers to the use of objective and subjective tests, signs and symptoms to characterize, quantify or evaluate the significance of any side effects produced by the administration of the active ingredient.
  • pain control is adequate refers to a level of pain the patient is willing to live with and does not significantly impair the patient's functioning in society or the patient's physiologic functions.
  • toxicity is acceptable refers to the absence of significant side effects and a level of toxicity that the patient is willing to live with and does not significantly impair the patient's functioning in society or the patient's physiologic functions.
  • a "COX-2 inhibitor” refers to a non-steroidal anti-inflammatory drug that is capable of directly targeting the COX-2 enzyme in a subject and inhibits at least some COX-1 activity, e.g., celecoxib.
  • a "mixed COX-1 and COX-2 inhibitor” refers to a non-steroidal anli -i nflammato ry drug that is capable of directly targeting both the COX-1 and COX-2 enzymes in a subject and inhibits at least some COX- 1 and COX-2 activity, e.g., ibuprofen.
  • a mixed COX-2 inhibitor can also include a COX-2 inhibitor such as celecoxib combined with one or more other therapeutic drugs for chronic diseases such as arthritis, diabetes, hypertension, hypercholesterolemia, and dementia.
  • Suitable therapeutic drugs may include, but are not limited to: aspirin, diclofenac (Cataflam, Voltaren), diflusnisal (Dolobid), etodolac (Lodine), fenoprofen (Nalfon), flubiprofen (Ansaid), ibuprofen (Motrin, Advil, Nuprin), indomethacin (Indocin), ketoprofen (Orudis), ketorolac (Toradol), meclofenamate, nabumetone (Relafen), naproxen (Naprosyn), oxaprozin (Daypro), phenylbutazone, piroxicam (Feldene), salicylate, sulindac (Clinor
  • hydrocortisone methylprednisolone, prednisolone, prednisone, triamcinolone, sulfonylureas, acetohexamide (Dymelor), chlorpropamide (Diabinese), glimepiride (Amaryl), glipizide (Glucotrol), glyburide (Micronase, DiaBeta), tolazamide (Tolinase), tolbutamide (Orinase), Biguanides, metformin (Glucophage), Alpha-glucosidase Inhibitors, acarbose (Precose), miglitol (Glyset), Thiazolidinedione Derivatives, pioglitazone (Actos), rosiglitazone
  • the combination can also include a "fixed dose combination” (FDC) or simply dosing with multiple pills each of a single agent to achieve a desired effect.
  • FDC fixed dose combination
  • the invention provides methods for individualized therapy of arthritic pain using a non-steroidal anti-inflammatory drug (NSAID), preferably celecoxib.
  • NSAID non-steroidal anti-inflammatory drug
  • the invention provides methods for predicting the outcome of the therapy arthritic pain with a composition comprising NSAID, preferably celecoxib.
  • the invention provides methods of using a NSAID, including aspirin, preferably celecoxib, in the manufacture of medicament for the treatment of arthritic pain.
  • This disclosure provides processes in accordance with invention comprising: administering a first formulation under a first regimen comprising a NSAID, preferably celecoxib, at a first dose to a patient suffering from arthritic pain; at a pre-specified time or times after administration of the first dose o the NSAID, measuring the NSAID' s concentration in the patient's blood (e.g., by a point of care device, or by other suitable techniques known in the art) at a plurality of time points after administering the first formulation resulting in a set of NSAID concentration/time data points; transforming the patient's NSAID concentration/time data points in to one or more pharmacokinetic (PK) parameters; comparing the patient's PK parameters to a predetermined ranges of values for such PK parameters and if one or more of the PK parameters fall outside of the PK
  • NSAID preferably celecoxib
  • the invention further provides methods for individualized drug therapy of arthritic pain with a NSAID, preferably celecoxib, comprising: administering a NSAID at a first dose under a first regimen to a patient suffering from arthritic pain; determining the concentration of the NSAID at a plurality of pre-specified time points after administration of the first dose of the NSAID; using the concentration/time data, deriving one or more pharmacokinetic (PK) parameters exhibited by the NSAID when administered to said patient; determining the level of efficacy and toxicity produced by the first dose and regiment; using the level of efficacy and toxicity produced by said first dose to determine a new dose of the NSAID;
  • PK pharmacokinetic
  • any suitable NSAID can be used in accordance with the invention, including without limitation, a COX- 1 -specific inhibitor, a COX-2-specific inhibitor, a mixed COX-1 and 2 inhibitor or a combination thereof.
  • the NSAID can be a salicylate, propionic acid derivative, acetic acid derivative, enolic acid (oxicam) derivative, anthranilic acid derivative (fenamatea ) or combinations thereof.
  • the NSAID can be, aspirin (acetylsalicylic acid), ibuprofen, naproxen, indomethacin, sulindac, piroxicam, clonixin, preferably celecoxib or a combination thereof.
  • the invention can be used with combinations of NSAIDs and other analgesic drugs such as lidocaine, opiates, acetaminophen, tricylic antidepressants, anticonvulsants, carbamazepine, gabapentin, and pregabalin; other anti- inflammatory drugs such as steroids and immunosuppressants.
  • NSAIDs and other therapies for arthritis including but not limited to, methotrexate and gold-salts.
  • the NSAID can be administered in accordance with the invention via any suitable route including, without limiting, orally, rectally, by inhalation, trans-cutaneously, by injection, intra-venously or intra-arterially.
  • the non-NSAID component of any combination therapy can be administered in accordance with the invention by any suitable route including, without limiting, orally, rectally, by inhalation, trans-cutaneously, by injection, intravenously or intra-arterially.
  • Any suitable regimen can be used in accordance with the invention to administer two or more drug components, including without limitation, simultaneously (within minutes of one another), substantially simultaneously (within an hour of one another) or at different times.
  • NSAID drug therapy e.g., a celecoxib therapy
  • a prescribed cholesterol regulator such as atorvastatin
  • Any suitable PK parameter or parameters can be used in accordance with the invention, including without limiting concentration, concentration time course, peak concentration, and time after administration to peak concentration, terminal half-life, AUC, bioavailability, absorption, distribution, metabolism, excretion, biotransformation, or a combination thereof.
  • any suitable method for the assessment of pain known to those of ordinary skill in the art can be used in accordnce with the invention, including, but not limited to, one- dimensional pain intensity scales, Wisconsin Brief Pain Questionnaire, Brief Pain Inventory, The McGill Pain Questionnaire and the short-form, McGill Pain Questionnaire (See Breivik et al: Assessment of pain, British Journal of Anaesthesia 2008, 101 (1): 17-24).
  • the following examples further illustrate the invention but, of course, should not be construed as in any way limiting its scope.
  • the approved prescribing information for Celebrex® as listed on its package insert for US/EU/ROW instructs that a physician should use lowest effective dose for the shortest duration consistent with treatment goals for the individual patient.
  • the package insert includes a 100 mg BID regimen:
  • Rheumatoid Arthritis 100 mg BID or 200 mg BID
  • JRA Juvenile Rheumatoid Arthritis
  • Ankylosing Spondylitis 200 mg once daily single dose or 100 mg BID.
  • AP Acute Pain
  • PD Primary Dysmenorrhea

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Computing Systems (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Primary Health Care (AREA)

Abstract

Methods for individualized therapy of arthritic pain using a non-steroidal anti-inflammatory drug (NSAID). Said methods comprise basing NSAID dose on each patient's pharmacokinetic and pharmacodynamic response to said NSAID.

Description

METHOD FOR INDIVIDUALIZED DRUG THERAPY
BACKGROUND OF THE INVENTION
[0001] The metabolism of a particular drug, and as a result the blood concentration and the duration of action achieved by that drug, can vary significantly in a general population. (See Chun-Yu et al.: Pharmacogenomics of adverse drug reactions: Implementing
personalized medicine, Human Molecular Genetics, 2012, 21, Review Issue 1, B58-B65). In the care of a patient suffering from a particular disease, a drug's efficacy against disases is a fundamental issue. However, side effects or "adverse drug reactions" ("ADRs") caused by a drug can profoundly impact the patient, thus requiring alterations in the treatment plan. (See Lazarou et al.: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998, 279(15): 1200-5). ADRs account for -7% of all hospitalizations and consistently rank as one of the most common causes of inpatient death in western countries. (See Pirmohamed & Park: Adverse drug reactions: back to the future. Br. J. Clin. Pharmacol., 2003, 55, 486^192; Wester et al.: Incidence of fatal adverse drug reactions: a population based study, Br. J. Clin. Pharmacol. 2007, 65:4, 573-579).
[0002] To guard against ADRs, administering the lowest dose of a drug to a patient that achieves the greatest efficacy of the drug is of paramount importance because 75%-80% of all ADRs are dose-related (i.e., the patient experiences a side effect because they are taking too high of a dose of a particular medication). (See Routlege et al.: Adverse drug reactions in elderly patients, Br J Clin Pharmacol 2004, 57:2 121-126; Lazarou et al.: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998,279 (15): 1200-5.; Melmon, KL, Morrelli, HF, Hoffman, BB, Nierenberg, DW. Melmon and Morrelli's Clinical Pharmacology: Basic Principles in Therapeutics. (3rd Edition), New York: McGraw-Hill, Inc., 1993). Despite the risks from ADRs, finding the lowest effective dose is often not addressed by conventional prescribing regimens. Additionally, the variability in individual responses to a drug significantly complicates finding the the lowest effective dose. The experiences ofprior patients may not be relevant to aparticular individual patient's regimen. Prescribers may be detered by a complexity of finding the lowest effective dose, and as a result, because many patients are maintained on an effective dose rather than the lowest effective dose, inadequate patient responses to the drug and/or responses with significant ADRs may occur.
[0003] Although differences in age, gender, and size contribute to the heterogeneity in drug metabolism, patients that are the same age, gender, and size can experience markedly different responses to the same drug dosage. Other factors which can influence the likelihood of ADRs include, without limitation, the administration of multiple drugs, disease state, past history of ADRs, allergic reactions, and genetic factors effecting the absorption, distribution, chemical alteration, and excretion of the drug. The ADRs from the class of drugs known as "non-steroidal ant i -i nfl ammatory drugs" ("NSAIDS") are well documented. (See, e.g..
Dieppe et al.: Balancing benefits and harms: the example of non-steroidal anti-inflammatory drugs, BMJ 2004, 329, 31-34; McGettigan & Henry: Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies, PLoS Med 2011 , 8(9): el001098. doi: 10.1371/journal.pmed.l001098; Aagaard & Hansen: Information about ADRs explored by pharmacovigilance approaches: a qualitative review of studies on antibiotics, SSRIs and NSAIDs, BMC Clinical Pharmacology 2009, 9:4; Siileyman: Anti-inflammatory and side effects of cyclooxygenase inhibitors, Pharm. Reports 2007, 59, 247-58). Further, although newer NSAIDS have somewhat reduced the risk for gastrointestinal bleeding, ulceration, and perforation, they still present risks to patients such as kidney failure, hepatic dysfunction, and cardiovascular events (e.g., stroke, hypertension, congestive heart failure) (See Celebrex® package insert; see also Bing, et al.:
Cyclooxygenase-2 inhibitors: is there an association with coronary or renal events?, Current Atherosclerosis Reports 2003;5:1 14-7.)
[0004] The danger of NSAID ADRs is particularly important in the elderly (i.e., age >65) where drug metabolism is quite heterogeneous. (See Singh et al: Gastrointestinal Drug Interactions Affecting the Elderly, Clin. Geriatr. Med 2014, 30: 1-15). As individuals age, they begin to experience diminished organ function, suffer from various diseases, and often take drugs that can interact resulting in an increased susceptibility to environmental and physical stressors (e.g., medications). As a result, seniors are generally more susceptible to the harmful side effects of NSAIDs, and yet generally receive the same dosing regimens as larger, younger individuals. (See McMillan & Hubbard: Frailty in older inpatients: what physicians need to know, Q. J. Med. 2012; 105: 1059-1065.; Smucker & Kontak: Adverse drug reactions causing hospital admission in an elderly population: experience with a decision algorithm, Journal of the American Board of Family Practice 1990, 3(2): 105-9; Montamat et al.: Management of drug therapy in the elderly. New England Journal of Medicine 1 89. 321 (5):303-9; and Recchia & Shear: Organization And Function Of An Adverse Drug Reaction Clinic. Journal Of Clinical Psychiatry 1994, 34:68-79). [0005] Celecoxib (sold under the brand name "Celebrex®") is a NSAID that has been approved for the treatment of arthritis for over 15 years. In vitro assays demonstrate that celecoxib is a potent inhibitor of prostaglandin synthesis with most of its activity resulting from its inhibition of COX-2. (See Suleyman et al.: Anti-inflammatory and side effects of cyclooxygenase inhibitors, Pharm. Reports 2007, 59, 247-58). Like other NSAIDs, celecoxib puts patients, in particular elderly patients, at risk for a number of serious ADRs. For example, the 1999 Celebrex® package insert warns that "the incidence of adverse experiences tended to be higher in elderly patients" (Celebrex® Package Insert. Searle & Co., 1999). Similarly, the 2003 Celebrex® package insert states that "there have been more spontaneous post-marketing reports of fatal gastrointestinal events and acute renal failure" regarding its use of in the elderly. The 2013 package insert indicates that "Celebrex® should be used with caution in [elderly] patients." The Celebrex® package insert advises that for osteoarthritis and rheumatoid arthritis, the lowest effective dose of Celebrex® should be sought for each patient.
[0006] Even the cyclooxgenase inhibitary activity of celecoxib appears to be variable (See McAdam et al.: Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. PNAS. 1999; 96:272-7.) FIG. 1 is a scatterplot graph from McAdams et al. displaying the relationship between LPS-stimulated plasma PGE2 ex vivo, an index of COX-2 activity, and log plasma concentrations of celecoxib at 2, 4, 6, and 24 hours after dosing. PGE2 is expressed as a percentage of predosing values. A variable dose-response is evident. (P , 0.01 vs. placebo).
[0007] A study by Bensen, et al. indicates that higher doses of celecoxib (100 mg and 200 mg twice a day) are similarly efficacious, while patients receiving the 100 mg dose of celecoxib also reported fewer side effects than those taking a 200 mg dose. (Table 1).
(Bensen, et al. .-Treatment of Osteoarthritis With Celecoxib, a Cyclooxygenase-2 Inhibitor: A Randomized Controlled Trial, Mayo Clinic Proceedings 1999, 74(11): 1095-1105) Table 1. Effect of Treatment on Signs and Symptoms of Osteoarthritis at 12 Weeks
Figure imgf000005_0001
BID= twice a day; WOMAC = Western Ontario and McMaster Universities
†Scale ranged from 1 (very good) to 5 (very poor). Patient improvement was defined as a reduction of at least 2 grades from baseline for grades 3 through 5 or a change in grade from 2 tl . Patient worsening was defined as an increase of at least 2 grades from baseline for grades ί through 3, or a change in grade from 4 to 5. KEY: t = P≤.05 vs placebo; § = Scale ranged from 0 to 96 with negative change indicating improvement // = < 05 vs celecoxib, 50 mg BID; <[] = Scale ranged from 0 to 24 with negative change indicating improvement; # = P≤.05 vs naproxen
[0008] Despite these acknowledgements, the Celebrex® dosage prescribed for the treatment of osteoarthritis, is standardized (e.g., 50, 100, 200 or 400 mg dosage forms) regardless of the gender and age of the patient receiving celecoxib. Furthermore, studies have shown that, on average, elderly patients receiving 100 mg celecoxib doses over a six week period reported almost identical reductions in pain as compared to patients receiving 200 mg celecoxib doses over a six week period. The subjects receiving the 100 nig dose of celecoxib also reported fewer side effects for the duration of the study. The results indicate that patients may experience the same celecoxib efficacy at lower, safer doses. Accordingly, there is a need for improved methods of using NSAIDs in the therapy of arthritic pain.
[0009] The present invention addresses the the wide variability in the responses individuals have to the same dosage of a drug by setting forth methods for individualizing drug therapy. The methods of the present invention individualize dosages a patient takes, thus maximizing the efficacy of one or more drugs at the lowest doses possible and at the point of care. The present invention can increase drug compliance, reduce costs, and most importantly improve the quality and safety of patient lives.
BRIEF SUMMARY OF THE INVENTION
[0010] The invention provides methods for individualized therapy of arthritic pain using a non-steroidal anti-inflammatory drug (NSAID). The high patient to patient variability in response to a dose of any NSAID makes the mere clinical monitoring of patients an inadequate way to treat patients with this class of drugs. Even the measurement of "blood levels'" (i.e., the ocasional measurement of the drug's concentration in the blood) is unlikely to lead to effective nontoxic regimens. Given the complexity of NSAIDs' dose response relationships, a more compressive set of metrics must employed in each patient. The methods claimed herein take advantage of a pharmacokinetic ("PK") analysis for each patient. As such, the claimed methods go beyond the measurement of a single blood level at a single time point. Instead, the claimed methods make use of data from several time points and take advantage of the full scope of PK parameters. There is no known method of predicting individual PK for celecoxib due to the complexity of human pharmacokinetics. As such there is no natural law known that can explain human pharmacokinetics; or if there are, the multitude of potential determining factors make defining such law impractical.
Therefore, the claimed method seeks to determined the individual PK directly.
[0011] The inventive methods disclosed herein comprise: administering to a first patient suffering from arthritic pain a first NSAID formulation; determining the NSAID 's concentration in the first patient's blood at a plurality of time points after the first NSAID formulation was administered to the first patient; transforming the first patient's NSAID concentration/time data points in to one or more PK parameters; comparing the first patient's values for said PK parameters to a predetermined ranges of values for each PK parameter and if one or more of the first patient's PK parameters fall outside o a predetermined range, designing a new NSAID formulation, wherein the dose of said NSAID can be different from that of the first NSAID formulation. As such, the types and amounts of excipients can also differ from those of the first NSAID formulation, or both. The new NSAID formulation is then administered to the first patient and the steps used to determine the PK parameters are repeated until all the PK parameters used are within said predetermined ranges, and if pain control is adequate and toxicity is tolerable, maintaining the first patient on the NSAID formulation at frequency of administration that satisfied the comparison within predetermined ranges.
[0012] Related methods for individualizing therapy of arthritic pain are disclosed herein.
BRIEF DESCRIPTION OF THE DRAWINGS
[0013] FIG. 1 is a scatterplot graph displaying the relationship between LPS-stimulated plasma PGE2 ex vivo, an index of COX-2 activity, and log plasma concentrations of celecoxib 2, 4, 6, and 24 hours after dosing. PGE2 is expressed as a percentage of predosing values. A steep but variable dose-response is evident. (P , 0.01 vs. placebo) (from McAdam et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. PNAS. 1999; 96:272-7.)
[0014] FIG. 2 depicts the pharmacokinetic parameters produced by different doses of celecoxib.
[0015] FIG. 3 displays the result of a meta-analysis of the one dose AUC from patients in different age groups.
DETAILED DESCRIPTION OF THE INVENTION
[0016] As used herein the phrase "individualized therapy" refers to a specific treatment regimen for a patient comprising the administration of one or more drugs, which is the result of analyzing pharmacokinetic and/or pharmacodynamic parameters of the subject to maximize drug efficacy at about the lowest dosage of the drug(s) possible.
[0017] As used herein "Arthritic pain" refers to any pain arising anatomically from the joints and their adjacent bones and non-osseous tissues. Any arthritic pain can be treated by the invention including, without limitation, any pain resulting from an auto-immune, infectious, inflammatory, proliferative, regenerative or degenerative process so involving the joints of an animal or human patient. As such, suitable pain treatable with the current invention includes pain from rheumatoid or osteo arthritis. [0018] As used herein, "formulation" or "a formulation" refers to a combination of active ingredients and excipients wherein each is present in a dosage form at fixed ratios to one another (i.e., fixed percentages of each ingrediant in the dosage form.)
[0019] As used herein, "first NSAID formulation" is the NSAID formulation that is administered to the patient to begin the process by which PK parameters are determined and "new NSAID formulation" is the formulation designed based on the PK parameters produced by the first NSAID formulation. To evaluate the PK parameters produced by the new NSAID formulation becomes the first NSAID formulation and the process is repeated. The new NSAID formulation may be a second formulation.
[0020] As used herein, the phrases "second formulation" and "second formulation under a second drug regimen" refer to the dosage of one or more drugs an individual receives after performing certain steps of the claimed invention (e.g., after comparing an patient's pharmacokinetic parameters to a predetermined range of values). The second formulation under a second regimen, can be, e.g., the same dosage of a drug administered in the first regimen, a lower dose, or a higher dose. In addition, there can be changes in any non-NSAID components of any combination therapy.
[0021] As used herein the phrases "first formulation under a first regimen" and "first formulation" refer to the dosage of one or more drugs an individual initially receives prior to performing one or more steps of the claimed invention. The first formulation under a first regimen, can be, e.g., the standard 100 mg or 200 mg dosages of celecoxib prescribed to patients over 60 kg twice daily for osteoarthritis.
[0022] As used herein, the phrase "NSAID concentration/time data points" refers to the amount of NSAID in a unit of volume (e.g., 1 ml of blood from a subject) at a given point in time before or after administration of the NSAID.
[0023] As used herein, the phrase "transforming the patient's NSAID concentration/time data points" refers to the application of mathematical operations, formulas, theories, and/or principles (e.g., a formula for calculating half life or a formula for calculating AUC), to the NSAID concentrations/time data points of an individual to derive PK parameters.
[0024] As used herein, the phrase "predetermined range of values" refers to a known range of values (e.g., pharmacokinetic parameters) associated with desirable drug efficacy at lower risk doses of a drug (e.g., the Cmax range corresponding to patients experiencing high drug efficacy at a low dose). The predetermined range of values may be derived from a statistical analysis of a population receiving variable and/or identical doses of one or more drugs. The predetermined range of values can readily be compared to a patient's values (e.g., pharmacokinetic values), associated with one or more drugs. In particular, the predetermined ranges are determined (i.e. derived) from other patients for whom there was improved pain levels without significant side effects.
[0025] As used herein, "Significant adverse drug reactions" refer to ADRs that the patient finds intolerable, impair physiologic functions, and/or put the patient at risk for immobility and/or death or combinations thereof.
[0026] As used herein "Significant side effects" refer to side effects that the patient finds intolerable, impair physiologic functions, and/or put the patient at risk for immobility and/or death or combinations thereof.
[0027] As used herein, "designing" refers to changes in the active agent's dose, formulation and/or regiment based on the patient data, using logic and the experience of one of ordinary skill in the art.
[0028] As used herein, "determining the level of efficacy" refers to the use of objective (e.g., pharmacokinetic) and subjective tests (e.g., pharmacodynamic), signs and symptoms to characterize, quantify or evaluate how well symptoms (e.g., pain) are controlled by the administration of the active ingredient (e.g., celecoxib).
[0029] As used herein, "determining the level of toxicity" refers to the use of objective and subjective tests, signs and symptoms to characterize, quantify or evaluate the significance of any side effects produced by the administration of the active ingredient.
[0030] As used herein, "pain control is adequate" refers to a level of pain the patient is willing to live with and does not significantly impair the patient's functioning in society or the patient's physiologic functions.
[0031] As used herein, "toxicity is acceptable" refers to the absence of significant side effects and a level of toxicity that the patient is willing to live with and does not significantly impair the patient's functioning in society or the patient's physiologic functions.
[0032] As used herein, a "COX-1 inhibitor" refers to a non-steroidal anti-inflammatory drug that is capable of directly targeting the COX-1 enzyme in a subject and inhibits at least some COX-1 activity, e.g., aspirin.
[0033] As used herein, a "COX-2 inhibitor" refers to a non-steroidal anti-inflammatory drug that is capable of directly targeting the COX-2 enzyme in a subject and inhibits at least some COX-1 activity, e.g., celecoxib. As used herein, a "mixed COX-1 and COX-2 inhibitor" refers to a non-steroidal anli -i nflammato ry drug that is capable of directly targeting both the COX-1 and COX-2 enzymes in a subject and inhibits at least some COX- 1 and COX-2 activity, e.g., ibuprofen.
[0034] As used here a mixed COX-2 inhibitor can also include a COX-2 inhibitor such as celecoxib combined with one or more other therapeutic drugs for chronic diseases such as arthritis, diabetes, hypertension, hypercholesterolemia, and dementia. Suitable therapeutic drugs may include, but are not limited to: aspirin, diclofenac (Cataflam, Voltaren), diflusnisal (Dolobid), etodolac (Lodine), fenoprofen (Nalfon), flubiprofen (Ansaid), ibuprofen (Motrin, Advil, Nuprin), indomethacin (Indocin), ketoprofen (Orudis), ketorolac (Toradol), meclofenamate, nabumetone (Relafen), naproxen (Naprosyn), oxaprozin (Daypro), phenylbutazone, piroxicam (Feldene), salicylate, sulindac (Clinoril), tolmetin (Tolectin), pregbalin, neurontin, beclomethasone, betamethasone, cortisone, dexamethasone,
hydrocortisone, methylprednisolone, prednisolone, prednisone, triamcinolone, sulfonylureas, acetohexamide (Dymelor), chlorpropamide (Diabinese), glimepiride (Amaryl), glipizide (Glucotrol), glyburide (Micronase, DiaBeta), tolazamide (Tolinase), tolbutamide (Orinase), Biguanides, metformin (Glucophage), Alpha-glucosidase Inhibitors, acarbose (Precose), miglitol (Glyset), Thiazolidinedione Derivatives, pioglitazone (Actos), rosiglitazone
(Avandia), troglitazone (Rezulin), enalapril, lisinopril perindopril, losartan, valsartan, diltiazem, nifedipine, amlodipine, diuretics, amiloride, frusemide, indapamide, atenolol, metoprolol, propanolol, alpha-blockers, doxazosin, prazosin, methyldopa, vasodilators, and hydralazine.
[0035] As used here the combination can also include a "fixed dose combination" (FDC) or simply dosing with multiple pills each of a single agent to achieve a desired effect.
[0036] The invention provides methods for individualized therapy of arthritic pain using a non-steroidal anti-inflammatory drug (NSAID), preferably celecoxib. In addition, the invention provides methods for predicting the outcome of the therapy arthritic pain with a composition comprising NSAID, preferably celecoxib. Further, the invention provides methods of using a NSAID, including aspirin, preferably celecoxib, in the manufacture of medicament for the treatment of arthritic pain.
[0037] The invention provides endpoints (i.e., an individualized drug therapy) based on the achievement of predetermined PK results, as well as the clinical condition of the patient.
[0038] This disclosure provides processes in accordance with invention comprising: administering a first formulation under a first regimen comprising a NSAID, preferably celecoxib, at a first dose to a patient suffering from arthritic pain; at a pre-specified time or times after administration of the first dose o the NSAID, measuring the NSAID' s concentration in the patient's blood (e.g., by a point of care device, or by other suitable techniques known in the art) at a plurality of time points after administering the first formulation resulting in a set of NSAID concentration/time data points; transforming the patient's NSAID concentration/time data points in to one or more pharmacokinetic (PK) parameters; comparing the patient's PK parameters to a predetermined ranges of values for such PK parameters and if one or more of the PK parameters fall outside of the
predetermined range, providing a second formulation under a second regimen wherein the second formulation has a different dose of NSAID, preferably celecoxib, from the first formulation, or different regimen. These steps will be repeated until the PK parameters are within a second predetermined range.
[0039] The invention further provides methods for individualized drug therapy of arthritic pain with a NSAID, preferably celecoxib, comprising: administering a NSAID at a first dose under a first regimen to a patient suffering from arthritic pain; determining the concentration of the NSAID at a plurality of pre-specified time points after administration of the first dose of the NSAID; using the concentration/time data, deriving one or more pharmacokinetic (PK) parameters exhibited by the NSAID when administered to said patient; determining the level of efficacy and toxicity produced by the first dose and regiment; using the level of efficacy and toxicity produced by said first dose to determine a new dose of the NSAID;
administering the new dose of the NSAID to the patient; and repeating the forgoing steps until pain control is adequate, toxicity is acceptable, and PK parameters are stable. The patient will thereafter be maintained at the final dose (i.e., an individualized drug therapy) that produced the results. However, if the patient has recurrent pain or toxicity again, one measures the PK parameters and adjust dose to provide the PK results determined by the original trials of the NSAID.
[0040] Any suitable NSAID can be used in accordance with the invention, including without limitation, a COX- 1 -specific inhibitor, a COX-2-specific inhibitor, a mixed COX-1 and 2 inhibitor or a combination thereof. As such, the NSAID can be a salicylate, propionic acid derivative, acetic acid derivative, enolic acid (oxicam) derivative, anthranilic acid derivative (fenamatea ) or combinations thereof. Accordingly, the NSAID can be, aspirin (acetylsalicylic acid), ibuprofen, naproxen, indomethacin, sulindac, piroxicam, clonixin, preferably celecoxib or a combination thereof. In addition, the invention can be used with combinations of NSAIDs and other analgesic drugs such as lidocaine, opiates, acetaminophen, tricylic antidepressants, anticonvulsants, carbamazepine, gabapentin, and pregabalin; other anti- inflammatory drugs such as steroids and immunosuppressants. Further, the invention can be used with combinations of NSAIDs and other therapies for arthritis, including but not limited to, methotrexate and gold-salts.
[0041] The NSAID can be administered in accordance with the invention via any suitable route including, without limiting, orally, rectally, by inhalation, trans-cutaneously, by injection, intra-venously or intra-arterially. The non-NSAID component of any combination therapy can be administered in accordance with the invention by any suitable route including, without limiting, orally, rectally, by inhalation, trans-cutaneously, by injection, intravenously or intra-arterially. Any suitable regimen can be used in accordance with the invention to administer two or more drug components, including without limitation, simultaneously (within minutes of one another), substantially simultaneously (within an hour of one another) or at different times.
[0042] Other treatments for chronic diseases can be included such as treatments for diabetes, cardiovascular diseases, dementia, cholesterol, and hypertension. For example, a method of individualizing an NSAID drug therapy (e.g., a celecoxib therapy), may be practiced in conjunction with the administration of a prescribed cholesterol regulator, such as atorvastatin.
[0043] Any suitable PK parameter or parameters can be used in accordance with the invention, including without limiting concentration, concentration time course, peak concentration, and time after administration to peak concentration, terminal half-life, AUC, bioavailability, absorption, distribution, metabolism, excretion, biotransformation, or a combination thereof.
[0044] Any suitable pharmacodynamic parameter or parameters can be used in accordance with the invention, including without limiting the physiological changes of cells, tissues and ligaments of a patient, patient or physician reported pain level, the frequency of side effects, or a combination thereof.
[0045] Any suitable method for the assessment of pain known to those of ordinary skill in the art can be used in accordnce with the invention, including, but not limited to, one- dimensional pain intensity scales, Wisconsin Brief Pain Questionnaire, Brief Pain Inventory, The McGill Pain Questionnaire and the short-form, McGill Pain Questionnaire (See Breivik et al: Assessment of pain, British Journal of Anaesthesia 2008, 101 (1): 17-24). [0046] The following examples further illustrate the invention but, of course, should not be construed as in any way limiting its scope.
EXAMPLE 1
[0047] The approved prescribing information for Celebrex® as listed on its package insert for US/EU/ROW instructs that a physician should use lowest effective dose for the shortest duration consistent with treatment goals for the individual patient. For four of the six approved indications the package insert includes a 100 mg BID regimen:
[0048] 1) Osteoarthritis (OA): 200 mg QD or 100 mg BID
[0049] 2) Rheumatoid Arthritis (RA): 100 mg BID or 200 mg BID
[0050] 3) Juvenile Rheumatoid Arthritis (JRA): 50 mg BID in patients 10-25 kg. 100 mg
BID in patients more than 25 kg
[0051] 4) Ankylosing Spondylitis (AS): 200 mg once daily single dose or 100 mg BID.
[0052] 5) Acute Pain (AP) and 5) Primary Dysmenorrhea (PD). 400 mg initially, followed by 200 mg dose if needed on first day. On subsequent days, 200 mg BID as needed
[0053] Unexpectedly, however, the inventor's analysis of the actual prescribing behavior using Evaluate Pharma/IMS database deteremined that the 200 mg is the predominant dose being prescribed by physicians by more than 10 to 1. These data are consistent with data from a MEPS survey (Table 2) and Medicaid survey (Table 3). In view of predominance of the 200 mg dosage form sales and the evidence that the 100 mg and 200 mg doses produce overlapping P and pharmacodynamic results, it is questionable that the package insert's admonition that "the lowest dose of Celebrex® should be sought for each patient" is followed. Instead, the data indicates that it is likely that there are numerous patients a risk for ADRs because their celecoxib dose is higher than it needs to be (i.e., e.g., 200 mg BID rather than 100 mg BID).
Table 2. MEPS Survey Data
Figure imgf000013_0001
Figure imgf000014_0001
Table 3. Prescribing information derived from Medicaid
Figure imgf000014_0002
EXAMPLE 2
[0054] The combined plots of published pharmacokinetic data including those from the Summary basis for approval are shown in FIG. 2. The variability of Celebrex®
pharmacokinetics were unexpectedly high. The PK results for the 200 mg dose shows a substantial overlap with that of the 100 mg dose. Accordingly, the dose proportionality may not be as is described by the package insert for Celebrex®. As a result of the failure to determine and pursue target PK ranges, in some instances patients receiving 100 mg patients may not get enough of the drug and the 200 mg patients may receive too much of the drug.
EXAMPLE 3
[0055] Applicant's meta analysis of the reported PK parameters in different populations demonstrates that the elderly show a higher variability than younger patients. For Example, when the applicant's meta analysis is presented in age-based subgroups, the elderly and younger patients demonstrate highly significant differences in the variability of AUC (FIG. 3). In other words, the most efficacious celecoxib dosage is highly individualized among the elderly. Unexpectedly, elderly here is defined as patients greater than >40 or >50, not the usually definition of elderly (age greater >65). Previously, there has been reported impaired PK with elderly and the package insert issued warning on impaired PK in elderly but did not suggest dose reduction. Our finding suggests that the issue is more substantial and more widespread and includes middle aged groups also.
[0056] That the variability of PK results within groups and the Cmax and AUG overlap between the 100 mg and 200 mg groups indicates that correctly dosing elderly patients to maximize celecoxib efficacy at the lowest doses possible depends on many individualized, unpredictable variables. Baased on the wide range of AUC values, some instances patients receiving 100 mg patients may not get enough of the drug and the 200 mg patients may receive too much of the drug (FIG. 2).
[0057] All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.
[0058] The use of the terms "a" and "an" and "the" and "at least one" and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The use of the term "at least one" followed by a list of one or more items (for example, "at least one of A and B") is to be construed to mean one item selected from the listed items (A or B) or any combination of two or more of the listed items (A and B), unless otherwise indicated herein or clearly contradicted by context. The terms "comprising," "having," "including," and "containing" are to be construed as open-ended terms (i.e., meaning "including, but not limited to,") unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., "such as") provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
[0059] Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those preferred embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.

Claims

CLAIMS We claim the following:
1. A method for individualized therapy of arthritic pain using a non-steroidal antiinflammatory drug (NSAID), comprising:
a. administering a first NSAID formulation comprising a first dose of a NSAID combined with specific excipients in specific amounts, to a first patient suffering from arthritic pain;
b. determining the NSAID' s concentration in the first patient's blood at a plurality of time points after the first NSAID formulation was administered to the first patient;
c. transforming the first patient's NSAID concentration/time data points in to one or more pharmacokinetic (PK) parameters;
d. comparing the first patient's values for said PK parameters to a predetermined ranges of values for each PK parameter and if one or more of the first patient's PK parameters fall outside of a predetermined range, designing a new NSAID
formulation, wherein the:
i. the dose of said NSAID is different from that of the first NSAID formulation;
ii. the types and amounts of excipients differ from those of the first NSAID formulation;
iii. or both;
e. administering the new NSAID formulation to the first patient;
f. repeating steps b-e until all the PK parameters used in step d are within said predetermined ranges, and
g. if pain control is adequate and toxicity is tolerable, maintaining the first patient on the NSAID formulation at frequency of administration that satisfied the comparison in step d.
2. The method of claim 1, wherein the NSAID is administered orally.
3. The method of claim 1, wherein said predetermined PK ranges are based the PK parameters of other patients suffering from arthritic pain who had been successfully treated with said NSAID such that pain control is adequate and toxicity is acceptable.
4. The method of claim 1 , wherein the NSAID comprises a COX-1 inhibitor, a COX-2 inhibitor, a mixed COX-1 and 2 inhibitor or a combination thereof.
5. The method of claim 4. wherein the COX- 1 inhibitor is aspirin.
6. The method of claim 1, wherein the NSAID is a COX-2 inhibitor.
7. The method of claim 6, wherein the COX-2 inhibitor is celecoxib.
8. The method of claim 1 , wherein the PK parameter used is one or more of
concentration, concentration time course, peak concentration, time after administration to peak concentration, terminal half-life, AUC, bioavailability, absorption, distribution, metabolism, excretion, biotransformation, or a combination thereof.
9. The method of any one of claims claim 1-8, further comprising administering one or more pharmaceutically active agents in addition to said NSAID at a pharmaceutically active doses.
10. The method of claim 9, wherein the additional pharmaceutically active agents are active agents used to treat central and peripheral nervous system disorders, cardiac arrhythmias, hyperlipidemia, hypertensive, angina, congestive heart failure, respiratory system disorders, gastrointestinal disorders, renal disorders, epilepsy, migraine , sleep disorders, anxiety, substance abuse, pain, parkinsonism, spasticity, psychiatric disorders, dementia, endocrine disorders, diabetes, thyroid disorders , gynecologic and obstetric conditions, lactation , urologic system disorders, immunologic disorders, bone and joint disorders, osteoporosis and osteomalacia, inflammatory disorders , disorders of the eyes, ears, nose, and throat, dermatologic system disorders, hematologic disorders , coagulation disorders , infectious diseases , neoplastic diseases, nutritional disorders , or allergic disorders.
11. The method of claim 10, wherein the NSAID and the one or more pharmaceutically active agents in addition to said NSAID are administered in a fixed dose combination.
PCT/US2015/011148 2014-06-08 2015-01-13 Method for individualized drug therapy Ceased WO2016114761A1 (en)

Priority Applications (34)

Application Number Priority Date Filing Date Title
KR1020157034125A KR20160098029A (en) 2015-01-13 2015-01-13 Method for individualized drug therapy
EP15878203.7A EP3245602A4 (en) 2015-01-13 2015-01-13 Method for individualized drug therapy
AU2015377253A AU2015377253A1 (en) 2015-01-13 2015-01-13 Method for individualized drug therapy
JP2017536310A JP2018508476A (en) 2015-01-13 2015-01-13 Methods for personalized drug therapy
CN201580077772.8A CN107408147A (en) 2015-01-13 2015-01-13 Method for Individual drug treatment
CA2973569A CA2973569A1 (en) 2015-01-13 2015-01-13 Method for individualized drug therapy
PCT/US2015/011148 WO2016114761A1 (en) 2015-01-13 2015-01-13 Method for individualized drug therapy
CA2956899A CA2956899A1 (en) 2014-06-08 2015-06-08 Fixed dose combination for pain relief without edema
EP15806490.7A EP3151822A4 (en) 2014-06-08 2015-06-08 Fixed dose combination for pain relief without edema
AU2015274895A AU2015274895A1 (en) 2014-06-08 2015-06-08 Fixed dose combination for pain relief without edema
PCT/US2015/034706 WO2015191460A1 (en) 2014-06-08 2015-06-08 Fixed dose combination for pain relief without edema
CN201580040734.5A CN106572984A (en) 2014-06-08 2015-06-08 Fixed dose combination for pain relief without causing edema
JP2016571720A JP2017517529A (en) 2014-06-08 2015-06-08 Combination of fixed doses to reduce pain without edema
EP15807276.9A EP3151823A4 (en) 2014-06-08 2015-06-08 Fixed dose combination for pain relief without edema
CN201580042156.9A CN106572985A (en) 2014-06-08 2015-06-08 Fixed dose combination for pain relief without edema
KR1020167015176A KR20160091349A (en) 2014-06-08 2015-06-08 Fixed dose combination for pain relief without edema
AU2015274908A AU2015274908A1 (en) 2014-06-08 2015-06-08 Fixed dose combination for pain relief without edema
PCT/US2015/034738 WO2015191473A1 (en) 2014-06-08 2015-06-08 Fixed dose combination for pain relief without edema
KR1020167015173A KR20160091348A (en) 2014-06-08 2015-06-08 Fixed dose combination for pain relief without edema
JP2017516649A JP2017517575A (en) 2014-06-08 2015-06-08 Fixed dose combination to reduce pain without edema
CA2956897A CA2956897A1 (en) 2014-06-08 2015-06-08 Fixed dose combination for pain relief without edema
US14/798,737 US20160022639A1 (en) 2014-07-14 2015-07-14 Fixed dose combination for pain relief without edema
US14/798,753 US20160008371A1 (en) 2014-07-14 2015-07-14 Fixed dose combination for pain relief without edema
TW104142786A TW201625307A (en) 2015-01-13 2015-12-18 Method for individualized drug therapy
PCT/US2016/012914 WO2016115057A1 (en) 2015-01-13 2016-01-11 Fixed dose combination for pain relief without edema
US14/993,037 US20160120885A1 (en) 2014-07-14 2016-01-11 Fixed dose combination for pain relief without edema
TW105109708A TW201642906A (en) 2014-06-08 2016-03-28 Fixed dose combination for pain relief without edema
TW105109706A TW201642854A (en) 2014-06-08 2016-03-28 Fixed dose combination for pain relief without edema
US15/298,222 US20170035787A1 (en) 2014-07-14 2016-10-19 Fixed Dose Combination for Pain Relief Without Edema
US15/360,971 US20170071956A1 (en) 2014-07-14 2016-11-23 Fixed Dose Combination for Pain Relief Without Edema
US15/490,883 US20170326109A1 (en) 2014-07-14 2017-04-18 Fixed Dose Combination for Pain Relief Without Edema
US16/173,924 US20190125727A1 (en) 2014-07-14 2018-10-29 Fixed dose combination for pain relief without edema
US16/183,638 US20190070201A1 (en) 2014-07-14 2018-11-07 Fixed dose combination for pain relief without edema
US16/206,953 US20190091243A1 (en) 2014-07-14 2018-11-30 Fixed dose combination for pain relief without edema

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2015/011148 WO2016114761A1 (en) 2015-01-13 2015-01-13 Method for individualized drug therapy

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2015/034706 Continuation-In-Part WO2015191460A1 (en) 2014-06-08 2015-06-08 Fixed dose combination for pain relief without edema
PCT/US2015/034738 Continuation-In-Part WO2015191473A1 (en) 2014-06-08 2015-06-08 Fixed dose combination for pain relief without edema

Related Child Applications (4)

Application Number Title Priority Date Filing Date
PCT/US2015/034738 Continuation-In-Part WO2015191473A1 (en) 2014-06-08 2015-06-08 Fixed dose combination for pain relief without edema
US14/798,737 Continuation-In-Part US20160022639A1 (en) 2014-07-14 2015-07-14 Fixed dose combination for pain relief without edema
US14/798,753 Continuation-In-Part US20160008371A1 (en) 2014-07-14 2015-07-14 Fixed dose combination for pain relief without edema
US14/993,037 Continuation-In-Part US20160120885A1 (en) 2014-07-14 2016-01-11 Fixed dose combination for pain relief without edema

Publications (1)

Publication Number Publication Date
WO2016114761A1 true WO2016114761A1 (en) 2016-07-21

Family

ID=56406160

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/011148 Ceased WO2016114761A1 (en) 2014-06-08 2015-01-13 Method for individualized drug therapy

Country Status (7)

Country Link
EP (1) EP3245602A4 (en)
JP (1) JP2018508476A (en)
KR (1) KR20160098029A (en)
CN (1) CN107408147A (en)
AU (1) AU2015377253A1 (en)
CA (1) CA2973569A1 (en)
WO (1) WO2016114761A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4267132A1 (en) * 2020-12-28 2023-11-01 Dr. Reddy's Laboratories Ltd. Celecoxib for treating pain
US12546762B2 (en) 2018-06-07 2026-02-10 Raysearch Laboratories Ab (Publ) Method and system for evaluation of drug concentration in blood, plasma or serum

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3792932A1 (en) * 2019-09-13 2021-03-17 Hill-Rom Services, Inc. Personalized vital sign monitors
CN116999560A (en) * 2022-04-30 2023-11-07 武汉思瓴生物科技有限公司 Drug combinations that can treat pain and their applications

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060078621A1 (en) * 2004-10-13 2006-04-13 Wedinger Robert S Method of providing customized drug delivery systems
US20070202170A1 (en) * 1999-12-22 2007-08-30 Pharmacia Corporation Dual-release compositions of a cyclooxygenase-2 inhibitor
WO2012166795A1 (en) * 2011-05-30 2012-12-06 String Therapeutics Inc. Methods and compositions for therapeutic drug monitoring and dosing by point-of-care pharmacokinetic profiling

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74539C2 (en) * 1999-12-08 2006-01-16 Pharmacia Corp Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070202170A1 (en) * 1999-12-22 2007-08-30 Pharmacia Corporation Dual-release compositions of a cyclooxygenase-2 inhibitor
US20060078621A1 (en) * 2004-10-13 2006-04-13 Wedinger Robert S Method of providing customized drug delivery systems
WO2012166795A1 (en) * 2011-05-30 2012-12-06 String Therapeutics Inc. Methods and compositions for therapeutic drug monitoring and dosing by point-of-care pharmacokinetic profiling

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3245602A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12546762B2 (en) 2018-06-07 2026-02-10 Raysearch Laboratories Ab (Publ) Method and system for evaluation of drug concentration in blood, plasma or serum
EP4267132A1 (en) * 2020-12-28 2023-11-01 Dr. Reddy's Laboratories Ltd. Celecoxib for treating pain

Also Published As

Publication number Publication date
CN107408147A (en) 2017-11-28
AU2015377253A1 (en) 2017-08-31
EP3245602A4 (en) 2018-09-05
EP3245602A1 (en) 2017-11-22
CA2973569A1 (en) 2016-07-21
KR20160098029A (en) 2016-08-18
JP2018508476A (en) 2018-03-29

Similar Documents

Publication Publication Date Title
Portenoy Treatment of cancer pain
Pahwa et al. Impact of dyskinesia on activities of daily living in Parkinson's disease: results from pooled phase 3 ADS-5102 clinical trials
Saengnipanthkul et al. Differentiation of patented crystalline glucosamine sulfate from other glucosamine preparations will optimize osteoarthritis treatment
EP3245602A1 (en) Method for individualized drug therapy
Toth Drug safety evaluation of pregabalin
US20190091243A1 (en) Fixed dose combination for pain relief without edema
Tolman et al. Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval
US20160199392A1 (en) Method for individualized drug therapy
Poudel et al. Irrational fixed dose combinations in Nepal: need for intervention
Manvelian et al. A phase I study evaluating the pharmacokinetic profile of a novel, proprietary, nano-formulated, lower-dose oral indomethacin
Hwang et al. Gabapentin versus Transdermal Fentanyl Matrix for the Alleviation of Chronic Neuropathic Pain of Radicular Origin: A Randomized Blind Multicentered Parallel‐Group Noninferiority Trial
Pergolizzi Jr et al. The potential role of an extended-release, abuse-deterrent oxycodone/acetaminophen fixed-dose combination product for the treatment of acute pain
Muranova et al. Levodopa/carbidopa/entacapone combination therapy
Hershey et al. Treatment of pediatric and adolescent migraine
Şermet et al. Analgesic prescription pattern in the management of dental pain among dentists in İstanbul
TW201625307A (en) Method for individualized drug therapy
Hollenack et al. The application of evidence-based principles of care in older persons (issue 4): pain management
Siddalingaiah et al. Evergreened drugs or evergreened profits?
JP2017517529A (en) Combination of fixed doses to reduce pain without edema
Ohta et al. Rotigotine transdermal patch does not make Parkinson disease patients sleepy during daytime
Clark et al. Pharmacological management of orofacial pain–a clinician’s guide
Stocchi et al. An evaluation of the efficacy and value of CVT-301 for the treatment of Parkinson’s disease
Naraharisetti et al. Effects of food on bioavailability of analgesics; resulting dosage and administration recommendations
Ravichandran et al. Knowledge, attitude and prescriptional practice about fixed dose combinations among medical practitioners in Tertiary care hospital
Prasetyo et al. Effectiveness of Stalevo Drug Usage in Parkinson's Patients: A Narrative Review

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 20157034125

Country of ref document: KR

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15878203

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2017536310

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2973569

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2015878203

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2015377253

Country of ref document: AU

Date of ref document: 20150113

Kind code of ref document: A